12
Mar
Azafaros RAINBOW study update: Completion of 12 week phase 2
Azafaros has just announced the successful completion of its 12-week Phase 2
Read more
07
Mar
New podcast episode: Rare Revelations – Rare Disease Day Edition featuring Patricia Durao
In the latest episode of the CATS Foundation Rare Revelations podcast, listeners
Read more
29
Feb
22
Feb
The CATS Foundation at the Externally-Led, Patient-Focused Drug Development (EL-PFDD) Meeting for GM2
Last week, the Cure & Action for Tay-Sachs (CATS) Foundation had the incredible opportunity
Read more
19
Feb
The CATS Foundation at WORLDSymposium 2024 – a review of a great week of science and research
We're thrilled to share the highlights from our experience at the recent
Read more
13
Feb
Poster presented at the WORLDSymposium 2024 about our Clinical Toolkit project
We were excited to share some of our work at the recent
Read more
22
Jan
Patient-Focused Drug Development (PFDD) meeting with the FDA for GM2 Gangliosidosis
Our friends at the National Tay-Sachs & Allied Diseases Association have been
Read more
28
Feb
WORLDSymposium 2023 poster – Empowering the GM1 and GM2 community with a co-created education resource about a natural history study
In February 2023 we were delighted to present a poster at the
Read more
28
Feb
WORLDSymposium 2023 poster – Collaboration between patient advocacy and industry to create a master protocol to investigate the novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosides and Ataxia-telangiectasia
In February 2023 we were delighted to present a poster at the
Read more